Abstract: DNA methyl transferase (DNMT) inhibitors can re-establish the expression of tumour suppressor genes in malignant diseases, but might also be useful in other diseases. Inhibitors in clinical use are nucleosidic cytotoxic agents that need to be integrated into the DNA of dividing cells. Here, we assessed the in vivo kinetics of a non-nucleosidic inhibitor that is potentially free of cytotoxic effects and does not require cell division. The non-specific DNMT inhibitor N-phthalyl-L-tryptophan (RG 108) was injected subcutaneously in rats. Blood was drawn 0, 0.5, 1, 2, 4, 6, 8 and 24 hr after injection and RG 108 in plasma was measured by high-performance liquid chromatography coupled to mass spectrometry. Trough levels and area under the curve (AUC) were significantly higher with multiple-dose administration and cytochrome inhibition. In this group, time to maximal plasma concentration (t max , mean AE S.D.) was 37.5 AE 15 min., terminal plasma half-life was approximately 3.7 h (60% CI: 2.1-15.6 h), maximal plasma concentration (C max ) was 61.3 AE 7.6 lM, and AUC was 200 AE 54 lmolÁh/l. RG 108 peak levels were not influenced by cytochrome inhibition or multiple-dose administration regimens. Maximal tissue levels (C max in lmol/kg) were 6.9 AE 6.7, 1.6 AE 0.4 and 3.4 AE 1.1 in liver, skeletal and heart muscle, respectively. We conclude that despite its high lipophilicity, RG 108 can be used for in vivo experiments, appears safe and yields plasma and tissue levels in the range of the described 50% inhibitory concentration of around 1 to 5 lM. RG 108 can therefore be a useful tool for in vivo DNMT inhibition.
DNA methylation plays an important role in transcriptional regulation. Aberrant transcriptional regulation is an important contributing factor to the pathogenesis of many diseases from cancer to heart failure, and its restitution represents a therapeutic strategy [1, 2] . This might be achieved by influencing DNA methylation with DNA methyl transferase (DNMT) inhibitors, as already established in oncology.
Reactivation of hypermethylated tumour suppressor genes by DNMT inhibition has entered clinical routine for the treatment of myelodysplastic syndromes and cutaneous lymphomas [3] . Inhibition of maintenance methylation during cell division leads to the dilution of DNA methylation and in turn to a progressive reactivation of tumour suppressor genes. Several nucleosidic inhibitors of DNMTs have been developed to serve this goal [4] , but the concept cannot be translated directly from malignant diseases to others involving transcriptional dysregulation. To be active, nucleosidic inhibitors such as azacytidine, decitabine and zebularine have to be integrated into the DNA [5] and require high DNA turnover. This is the case in malignantly transformed cells, but not in terminally differentiated cells like neurons or cardiac myocytes. Moreover, all these inhibitors exert myelosuppressive off-target effects [6] . As in malignant diseases, highly active compounds are needed for short-term therapy, toxic side effects are usually tolerated given the diseases' aggressive nature but conversely prevent their use for non-malignant diseases. The relatively new observation that DNA methylation alterations are involved in other pathologies like diabetes [7] , neurological disorders [8] and cardiovascular diseases [9] necessitates small-molecule DNMT inhibitors that are active in terminally differentiated cells and are free of cytotoxic side effects. Moreover, as potentially cytotoxic compounds are not feasible for long-term therapy, non-nucleosidic inhibitors could prove additionally beneficial for the recent concept of epigenetic cancer prevention and maintenance therapy [10] .
The group of non-nucleosidic compounds that exhibit DNMT-inhibiting activity comprises various structurally heterogeneous compounds: nanaomycin A [11] , N-phthalyl-Ltryptophan (RG 108), psammaplin A [12] , genistein [13] , epigallocatechin gallate (EGCG [14] ) and substances in clinical use for other effects, such as procainamide [15] and hydralazine [16] . Some of these compounds are described to act more or less specifically on a certain DNMT isoform, inhibiting either maintenance methylation by DNMT1 or de novo methylation by DNMT3a or DNMT3b. Several disadvantages prevented the in vivo use of most of them. Among them are unacceptable kinetic and dynamic properties such as dissociation constants (K i -values) or 50% inhibitory concentration (IC 50 -values) in the micromolar range. For example, the K ivalue for EGCG has been described as~7 lM on mixed DNMTs [14] , the IC 50 of nanaomycin A as~0.5 lM [11] . Genistein inhibits DNMT1 at 50 lM [13] and published IC 50 values for RG 108 range from 115 nM [17] to much higher concentrations needed [18, 19] up to a mere 20% inhibition at 100 lM [20] . Several reports now describe the IC 50 or effective concentration of RG 108 around 1-5 lM [21] [22] [23] .
Moreover, the bioavailability of several compounds is not yet described and many of the substances that exhibit DNMTinhibiting properties in vitro are not suitable for in vivo use due to their high lipophilicity, bulky structure or other kinetic disadvantages. RG 108 has been specifically developed as a competitive non-nucleosidic DNMT inhibitor by structure-based drug design and virtual screening [17, 24] . It has been widely used since its discovery [1, 21, 25] including a local application in vivo [26, 27] . RG 108 fulfils four of five criteria of Lipinski's rule of five for kinetically suitable drugs -maximally 5 hydrogen bond donors, no more than 10 hydrogen bond acceptors and a molecular weight below 500 D. It presumably fails to fulfil the last though, an octanol-water partition coefficient log P below 5 [28] . As a lipophilic substance constituted of benzene rings, heterocyclic aromatic rings and very few polar groups, it is expected to be rapidly distributed to adipose tissue. Additionally, it has been associated with cytochromes in high-throughput screening experiments (CYP2C19 substrate, CHEMBL1613777) and induced CYP1A2 and CYP1B1 in own unpublished data. Here, we sought to establish the pharmacokinetics of RG 108 in a rat model in the absence and presence of cytochrome P450 inhibition.
Materials and Methods
Animals. Male Wistar rats (n = 16, 120-160 g) were obtained from Charles River (Sulzbach, Germany). The use of animals was consistent with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996) and the experimental protocol was approved by the local Animal Welfare Committee of the City of Hamburg, Germany (approval #08/14) and thereby required to comply with European Union Directive 86/609/EEC.
Reagents. A total of 2 mg of the non-specific DNMT inhibitor N-phthalyl-L-tryptophan (RG 108; ApexBio, Houston, TX, USA) was dissolved in a mixture of 33 ll dimethyl sulfoxide (DMSO; Sigma-Aldrich, Germany) and 15 ll ethanol (Sigma-Aldrich). The mixture was topped up to 400 ll with corn oil (Sigma-Aldrich). We evaluated different solvents and found RG 108 initially soluble only in ethanol or DMSO. We thus decided to use 33 ll of DMSO to keep the DMSO concentration below 10% of injected volume and 15 ll of ethanol to not exceed 0.8& estimated maximal plasma ethanol concentration given an average circulating blood volume of 19 ml in rat.
Ketoconazole in chow for cytochrome inhibition was obtained from Sigma-Aldrich and added to rat standard chow at 0.03% (Altromin Spezialfutter, Lage, Germany).
Study protocol and surgical technique. The study animals were divided into four groups comprising 4 animals each for plasma concentration analysis and one additional group of 5 animals for tissue concentration analysis. Groups for plasma concentration analysis were assigned numbers from 1 to 4. Group 1 received a single subcutaneous dose of RG 108 in the absence of the cytochrome inhibitor ketoconazole in chow. In group 2, a single dose of RG 108 was administered in rats treated with 0.03% of the cytochrome inhibitor ketoconazole in chow for at least 4 days prior to the experiments. Group 3 rats were treated daily with RG 108 for 3 days before blood samples were taken but received no ketoconazole. Group 4 animals were treated daily with RG 108 for 3 days and received ketoconazole in chow (table 1) . The subcutaneous route of application was chosen for its reproducibility, as intraperitoneal application might lead to injection in the intestines, gavage would have added complexity as the oral bioavailability of RG 108 is unknown and water insolubility prevented administration via drinking water. After the application of 2 mg RG 108, blood was drawn at 0, 0.5, 1, 2, 4, 6, 8 and 24 hr after injection. For this procedure, animals were anaesthetized by 2%-isoflurane inhalation and ventilated with 100% oxygen (0.7 ml/100 g, 90/min). Animals were placed in a supine position, a 1.5 cm-median cut along the neck was performed and the underlying structures carefully prepared to reveal the jugular vein. After exposure of the vein, it was punctured using a 26-G needle (0.40 9 20 mm; Braun, Melsungen, Germany) and 150 ll of blood was aspirated. Haemostasis was ensured and the skin closed with running sutures (5-0 Prolene; Ethicon, Norderstedt, Germany). During the time course experiment, this procedure was repeated several times. After the last sampling timepoint, the animals were killed by organ harvesting in deep anaesthesia with 5% isoflurane and concomitant buprenorphine administration (0.01 mg/kg body-weight, s.c.), and ventilation was carried out with 100% oxygen (0.7 ml/100 g, 90/min). For tissue sampling, animals were killed in a similar manner 0.5 h after RG 108 injection.
Sample preparation and compound extraction. Blood samples were centrifuged at 4°C and 9300 9 g for 15 min. A total of 50 ll of plasma supernatant was mixed with 150 ll of ice-cold acetonitrile to extract small-molecular lipophilic substances including RG 108 and centrifuged again for 15 min at 4°C and 9300 9 g. A total of 150 ll of supernatant was removed and stored at À80°C until measurement. Snap-frozen tissue was pulverized by mechanical disruption on liquid nitrogen. A total of 50 mg of each sample was subjected to acetonitrile extraction as described before and stored at À80°C until measurement. To determine the stability of the compound when stored in acetonitrile at À80°C, we re-analysed one sample after 8 months of storage and detected no drop in RG 108 concentration over time.
To investigate cellular and protein binding of RG 108, the compound was spiked into 150 ll fresh whole rat blood anticoagulated with EDTA to a final concentration of 60 lM. Blood was centrifuged at 4°C and 9300 9 g for 15 min, and 50 ll of serum was mixed with 150 ll saturated ammonium sulphate solution, incubated for 1 h at room temperature and then centrifuged again at 4°C and 9300 9 g for 15 min. To analyse serum levels, 50 ll of supernatant was subjected to acetonitrile extraction as described above; for protein binding analysis, the ammonium sulphate/protein pellet was dissolved in 180 ll acetonitrile and centrifuged as described before, and supernatant was analysed. Both solutions were kept at À80°C until measurement. To estimate corpuscular binding, the missing RG 108 was calculated from analysed protein-bound and free fraction. . All data were recorded and analysed using Analyst software (AB Sciex). Separation was carried out on a 150 9 2.1 mm, 5 lm Eclipse XDB C 18 column (Agilent) using methanol containing 0.1% formic acid (solvent A) and water containing 0.1% formic acid (solvent B) as mobile phase. The gradient used was as follows: 1 min isocratic 30% solvent A was linearly raised for 6 min to 95% solvent A followed by further 3 min isocratic 95% solvent A. The column was then flushed back to starting conditions, equilibrated and tempered at 40°C. Flow rate was 250 ml/min. All measurements were carried out using negative ionization and in multiple reaction monitoring (MRM) mode. A Turbo V Source was used for the ionization of samples using zero-grade air as nebulizer and auxiliary gas, while nitrogen was used as curtain gas and collision gas. Source parameters were as follows: curtain gas 1.72 9 10 5 pa, nebulizer gas 2.41 9 10 5 pa, auxiliary gas 3.10 9 10 5 pa, collision gas 1.33 9 10 À2 pa, ion spray voltage À4500 V and source temperature 350°C. MRM transitions were as follows: m/z 333?160 was used as a quantifier [declustering potential (DP): À45 V; entrance potential (EP): À2 V; cell entrance potential (CEP): À14 V; collision energy (CE): À20 V; collision cell exit potential (CXP): À16 V] and m/z 333?132 was used as a qualifier (DP: À45 V, EP: À2 V, CEP: À14 V, CE: À52 V, CXP: 0 V). To evaluate the influence of co-eluting substances from matrix, matrixmatched calibration with spiked blank plasma samples from rats was used. A recovery rate of 88% was calculated. Results were not corrected for recovery rates.
Statistics. All calculations were carried out with GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA). Pharmacokinetic parameters are given as mean AE standard deviation (S.D.), unless otherwise stated. The statistical test for all group comparisons was oneway ANOVA, followed by Bonferroni's post-test for multiple comparisons.
Results

Plasma concentrations.
RG 108 pharmacokinetics were tested in the absence and presence of cytochrome inhibition and at single-and multiple-dose administration. During the time of administration of the compound, we did not observe behavioural changes or other apparent effects. Figure 1A shows plasma concentrations in group 4 rats over time (multiple dose, ketoconazole). RG 108 was rapidly absorbed from subcutaneous depots, as time to maximal plasma concentration (t max , mean AE S.D.) was short at 37.5 AE 15 min. Logarithmic depiction revealed a two-phase plasma concentration-time curve, likely comprising an initial distribution phase and an excretion/metabolism phase ( fig. 1C) . Terminal half-life could only be calculated approximately due to large sampling intervals during the second phase of elimination and was 3.7 h (60% CI: 2.1-15.6 h). Maximal plasma concentration (C max ) was 20.5 AE 2.5 mg/l (61.3 AE 7.6 lM), trough plasma concentration (C min ) 0.5 AE 0.7 mg/l (1.5 AE 1.9 lM) and the area under the curve (AUC) was 66.8 AE 18.1 mgÁh/l (200 AE 54 lmolÁh/l).
We additionally investigated kinetics in groups 1 (single dose only), 2 (ketoconazole) and 3 (multiple dose). Basic pharmacokinetic parameters are given in table 2. T max and half-life did not differ among groups (data not shown, fig. 1B ), nor did C max differ (table 2, fig. 2A ). AUC and plasma concentrations 8 h after administration were signifi- cantly higher in group 4 and remained above the detection limit at 24 h, while trough concentrations fell below detection level in groups without both cytochrome inhibition and multiple-dose administration (table 2, fig. 2B ,C).
Tissue concentrations.
To assess concentrations of RG 108 in important organs, we included liver, heart and skeletal muscle in the analysis. Organs were harvested at plasma t max , about 37 min after administration, assuming rapid distribution of the compound between plasma and tissue due to the compound's high lipophilicity.
C max values for tissues were considerably lower than plasma concentrations: 2.5 AE 2.3 mg/kg tissue (6.9 AE 6.7 lmol/kg) in liver, 0.5 AE 0.4 mg/kg tissue (1.6 AE 1.1 lmol/kg) in skeletal and 1.1 AE 1.0 mg/kg tissue (3.4 AE 3.3 lmol/kg) in heart muscle ( fig. 3A) .
Cellular binding.
To investigate binding to blood cells, RG 108 was spiked into whole rat blood anticoagulated with EDTA at a final concentration of 60 lM. We sought to evaluate corpuscular and protein binding by separation of plasma, protein and cells and measured RG 108 concentrations in plasma and protein. The cell-bound fraction was calculated based on the resulting values. Although this calculation may overestimate cell-bound RG 108 because of incomplete preparation and detection of free and proteinbound compound, it provides an estimate of the high protein and cellular binding of the lipophilic compound ( fig. 3B ).
Discussion
To evaluate the therapeutic potential of DNMT inhibition in non-malignant diseases in animal models, non-nucleosidic DNMT inhibitors without cytotoxic properties are indispensable. To our knowledge, no convincing DNMT inhibitor has been used in in vivo studies systemically so far. This is likely attributable to the low potency, unknown pharmacokinetics and unfavourable chemical properties of most compounds of this group [18] . To bridge this experimental gap, we set out to establish the pharmacokinetics of one of the best evaluated non-nucleosidic DNMT inhibitors, RG 108 [17] . The data show that once-daily subcutaneous injections suffice to reach peak plasma concentrations above IC 50 and, in the presence of cytochrome P450 inhibition and multiple-dose administration, trough levels close to recently published IC 50 values or effective concentrations of 1-5 lM [21, 23] . Although systematic phenotyping of the animals was not in the scope of this study, we observed no evident effects on the animals. The injection sites were free of inflammation and the animals showed no changes in behaviour, neither regarding food intake, nor movement or social behaviour. While this is desirable, it also points to a potential disadvantage of nonnucleosidic DNMT inhibitors that likely have no obvious short-term effects despite their ability to efficiently exhibit demethylating properties in living cells [17] . This makes monitoring of pharmacodynamic efficacy difficult and plasma concentration level determination indispensable for kinetic analysis.
The shape of the plasma concentration-time curve argues for a two-phase elimination process. This observation is in line with the high lipophilicity of the compound. The initial rapid decrease in plasma concentration is presumably attributable to distribution to more lipophilic compartments, whereas the following beta-phase would then reflect whole animal clearance. The calculated terminal t 1/2 is intended to provide a rough impression of the dynamics of plasma concentrations. Sampling intervals unfortunately did not allow for more precise calculation in group 4 and the rapid decline of plasma concentrations below the detection level in the remaining groups precluded any t 1/2 calculation in these groups.
RG 108 is a substrate of CYP2C19 (Chembl bioactivity assay CHEMBL1613777; https://www.ebi.ac.uk/chembl/assay/ inspect/CHEMBL1613777) and induced CYP1A2 and CYP1B1 in rat heart cells (own unpublished data), providing the rationale to test its pharmacokinetics also in the presence of broad-spectrum cytochrome inhibition. We chose ketoconazole, which, in addition to CYP3A4 [29] , inhibits CYP1A2 and other cytochrome P450 isoenzymes in rat with far less specificity towards CYP3A4 than in human beings [30, 31] . As expected, ketoconazole augmented RG 108 plasma concentration at 8 h, trough concentrations and AUC, but this effect was observed only in the group of animals treated repeatedly with RG 108 and ketoconazole. Thus, it is not clear whether multiple-dose administration or cytochrome inhibition have the most pronounced effect on bioavailability. Multiple-dose administration could theoretically affect trough concentrations and AUC, but this may be counteracted by accelerated degradation due to cytochrome induction in the multiple-dose/nocytochrome inhibition group. Such an induction effect, together with overall high fluctuations, would explain that trough concentrations and AUC were only significantly higher with both multiple dosing and cytochrome inhibition. We therefore believe that both interventions will be beneficial in future animal studies using RG 108.
Overall, despite the conceivably unfavourable pharmacokinetics of RG 108 [18, 28] , we show that the compound can be used as an experimental tool in vivo. While this study was not designed as an in-depth analysis of in vivo characteristics of RG 108, the basic pharmacokinetic information should facilitate further experimental in vivo use of the compound. We show that daily subcutaneous administration of about 12.5 mg RG 108 per kg body-weight together with cytochrome inhibition results in plasma and tissue concentrations in the IC 50 range. 
